Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Next Previous
Trial Profile

A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; Tobevibart (Primary) ; Peginterferon alfa
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MARCH
  • Sponsors Vir Biotechnology

Most Recent Events

  • 09 May 2025 According to a Vir Biotechnology media release, detailed data were presented today at the European Association for the Study of the Liver (EASL) congress in Amsterdam (The Netherlands).
  • 09 May 2025 Results 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha (PEG-IFNa) in participants with chronic hepatitis B (CHB) were presented in Vir Biotechnology media release,
  • 24 Apr 2025 According to a Vir Biotechnology media release, The Company will present 24 Week post-treatment follow-up data from the MARCH Phase 2 clinical study evaluating combinations of tobevibart and elebsiran, alone, or in combination with pegylated interferon alfa (PEG-IFN alpha), in participants with chronic hepatitis B at the upcoming European Association for the Study of the Liver (EASL) Congress 2025 in Amsterdam (The Netherlands), May 7-10.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top